Blood use during extracorporeal membrane oxygenation

Area of Science:

• Neonatal Medicine
• Transfusion Medicine
• Cardiovascular Surgery

Background:

• Extracorporeal membrane oxygenation (ECMO) is a life-support measure for neonates with critical cardiorespiratory failure.
• Transfusion practices during neonatal ECMO are not standardized and may impact patient outcomes and blood bank resources.
• Previous reports suggested significant transfusion burdens associated with neonatal ECMO programs.

Purpose of the Study:

• To analyze transfusion requirements and outcomes in neonatal patients undergoing ECMO.
• To evaluate the impact of neonatal ECMO on hospital transfusion services.
• To assess the incidence of transfusion-related complications such as cytomegalovirus (CMV) infection and graft-versus-host disease (GVHD).

Main Methods:

• Retrospective analysis of transfusion records from 91 neonatal patients treated with ECMO.
• Documentation of daily blood product usage (red blood cells, fresh-frozen plasma, platelets).
• Review of transfusion protocols, including blood product types, washing, irradiation, and CMV testing.

Main Results:

• Mean daily transfusion requirements: 250 mL RBCs, 80 mL FFP, 2 units platelets.
• Average ECMO duration was 4.6 days.
• No cases of posttransfusion CMV infection or GVHD were observed; hemolysis in 8 patients was linked to ECMO circuit occlusions.
• Survival rate post-ECMO was high (90%).

Conclusions:

• Neonatal ECMO necessitates a manageable volume of blood products.
• Standard transfusion practices (non-washed, non-irradiated, non-CMV tested RBCs and plasma) appear safe in this neonatal ECMO population.
• Active neonatal ECMO programs place a minimal burden on hospital transfusion services, contrary to previous assumptions.